Treatment of depression associated with age-related macular degeneration: A double-blind, randomized, controlled study

Annals of Clinical Psychiatry

Volumn 23, Issue 4, 2011, Pages 277-284

  Brody, Barbara L ^a   Field, Linda C ^a   Roch Levecq, Anne Catherine ^a   Moutier, Christine Y ^b   Edland, Steven D ^a   Brown, Stuart I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age related macular degeneration; Crossover trial; Escitalopram; Major depression; Minor depression

Indexed keywords

ESCITALOPRAM; PLACEBO; ANTIDEPRESSANT AGENT; CITALOPRAM;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HUMAN; INSOMNIA; LOOSE FECES; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SOMNOLENCE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SWEATING; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RETINA MACULA DEGENERATION;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; CROSS-OVER STUDIES; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84858327888     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes. 2006;4:97.
2. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108:1893-1900. (Pubitemid 32905951)
3. Gottlieb JL. Age-related macular degeneration. JAMA. 2002;288:2233-2236. (Pubitemid 35291747)
4. Banerjee A, Kumar S, Kulhara P, et al. Prevalence of depression and its effect on disability in patients with age-related macular degeneration. Indian J Ophthalmol. 2008;56:469-474.
5. Rovner BW, Pasternak R, Casten R. A pilot study of sertraline for depression in age-related macular degeneration. Am J Geriatr Psychiatry. 2006;14:718-719. (Pubitemid 44196275)
6. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J NeurolNeurosurg Psychiatry. 2005;76:i48-i52. (Pubitemid 40293043)
7. Bekelman DB, Havranek EP, Becker DM, et al.Symptoms, depression, and quality of life in patients withheart failure. J Card Fail. 2007;13:643-648. (Pubitemid 47513542)
8. Sullivan M, Levy WC, Russo JE, et al. Depression andhealth status in patients with advanced heart failure: a prospectivestudy in tertiary care. J Card Fail. 2004;10:390-396. (Pubitemid 41080219)
9. Lebowitz BD, Pearson JL, Schneider LS, et al.Diagnosis and treatment of depression in late life.Consensus statement update. JAMA. 1997;278:1186-1190. (Pubitemid 27422429)
10. Kanner AM, Barry JJ. The impact of mood disorders inneurological diseases: should neurologists be concerned?Epilepsy Behav. 2003;4:S3-S13. (Pubitemid 37428232)
11. van Melle JP, de Jonge P, Spijkerman TA, et al.Prognostic association of depression following myocardialinfarction with mortality and cardiovascular events: ameta-analysis. Psychosom Med. 2004;66:814-822. (Pubitemid 39552863)
12. Ang DC, Choi H, Kroenke K, et al. Comorbiddepression is an independent risk factor for mortalityin patients with rheumatoid arthritis. J Rheumatol.2005;32:1013-1019. (Pubitemid 40828071)
13. Cimpean D, Drake RE. Treating co-morbid chronicmedical conditions and anxiety/depression. EpidemiolPsychiatr Sci. 2011;20:141-150.
14. Katon WJ. Epidemiology and treatment of depressionin patients with chronic medical illness. Dialogues ClinNeurosci. 2011;13:7-23.
15. First MB, Gibbon M, Spitzer RL, et al. User's guidefor the Structured Clinical Interview for DSM-IV AxisI Disorders. New York, NY: American PsychiatricPublishing; 1997.
16. Hamilton M. A rating scale for depression. J NeurolNeurosurg Psychiatry. 1960;23:56-62.
17. Williams JB. A structured interview guide for theHamilton Depression Rating Scale. Arch Gen Psychiatry.1988;45:742-747.
18. Katzman R, Brown T, Fuld P, et al. Validation ofa short Orientation-Memory-Concentration Test ofcognitive impairment. Am J Psychiatry. 1983;140:734-739. (Pubitemid 13094139)
19. Wade A, Michael Lemming O, Bang Hedegaard K.Escitalopram 10 mg/day is effective and well tolerated ina placebo-controlled study in depression in primary care.Int Clin Psychopharmacol. 2002;17:95-102. (Pubitemid 34442189)
20. Hamilton M. The assessment of anxiety states by rating.Br J Med Psychol. 1959;32:50-55.
21. Mangione CM, Lee PP, Pitts J, et al. Psychometricproperties of the National Eye Institute Visual FunctionQuestionnaire (NEI-VFQ). NEI-VFQ Field TestInvestigators. Arch Ophthalmol. 1998;116:1496-1504. (Pubitemid 28520671)
22. Brody BL, Williams RA, Thomas RG, et al. Agerelatedmacular degeneration: a randomized clinicaltrial of a self-management intervention. Ann Behav Med.1999;21:322-329.
23. Bailey IL, Lovie JE. New design principles forvisual acuity letter charts. Am J Optom Physiol Opt.1976;53:740-745. (Pubitemid 8033316)
24. Fleiss JL. The design and analysis of clinical experiments.New York, NY: John Wiley and Sons, Inc.; 1986.
25. R Development Core Team. The R Project forStatistical Computing. http://www.R-project.org.Accessed August 25, 2011.
26. American Psychiatric Association. Handbook of psychiatricmeasures. Washington, DC: American PsychiatricAssociation; 2000.
27. Rapaport MH, Judd LL. Minor depressive disorderand subsyndromal depressive symptoms: functionalimpairment and response to treatment. J Affect Disord.1998;48:227-232. (Pubitemid 28244225)
28. Fournier JC, DeRubeis RJ, Hollon SD, et al.Antidepressant drug effects and depression severity: apatient-level meta-analysis. JAMA. 2010;303:47-53.
29. Brody BL, Roch-Levecq AC, Thomas RG, et al. Selfmanagementof age-related macular degeneration at the6-month follow-up: a randomized controlled trial. ArchOphthalmol. 2005;123:46-53. (Pubitemid 40105428)
30. Brody BL, Roch-Levecq AC, Kaplan RM, et al.Age-related macular degeneration: self-managementand reduction of depressive symptoms in a randomized,controlled study. J Am Geriatr Soc. 2006;54:1557-1562. (Pubitemid 44564151)